Last reviewed · How we verify
NCT03773510: TRADITIONS
Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin
Phase 3 trial testing Trabectedin discontinuation in Leiomyosarcoma. Withdrawn.
1 October 2025
Quick facts
| Lead sponsor | Italian Sarcoma Group |
|---|---|
| Phase | Phase 3 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 28 February 2019 |
| Primary completion | 1 October 2025 |
| Estimated completion | 1 October 2025 |
| Sites | 15 locations across Italy |
Drugs / interventions tested
- Trabectedin discontinuation — full drug profile →
- Trabectedin continuation — full drug profile →
Conditions studied
- Leiomyosarcoma — all drugs for Leiomyosarcoma →
- Liposarcoma — all drugs for Liposarcoma →
- Synovial Sarcoma — all drugs for Synovial Sarcoma →
Sponsor
Italian Sarcoma Group — full company profile →
Who can join
18 and older, any sex, with Leiomyosarcoma or Liposarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Two arm, randomized, open-label study, to determine the best time to secondary resistance between responding patients who discontinue treatment and resumed Trabectedin at the time of progression versus patients who continued treatment until progression. T
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03773510
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Leiomyosarcoma
Currently open trials in the same condition.
- NCT07169344 — Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma · Phase 2 · recruiting
- NCT06528769 — Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma · Phase 2 · recruiting
- NCT06975293 — STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants · Phase 1, PHASE2 · recruiting
- NCT06849986 — IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) · Phase 2 · recruiting
- NCT06308419 — A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcoma · Phase 1 · recruiting
Other Italian Sarcoma Group trials
Trials by the same sponsor.
- NCT07265661 — Surgical Timing After Preoperative Hypofractionated Radiotherapy for Localized Extremity and Trunk Soft Tissue Sarcoma · NA · not yet recruiting
- NCT07328425 — Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS · Phase 2 · recruiting
- NCT06375941 — Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars · recruiting
- NCT04274023 — Study on TSR-042 in Advanced Clear Cell Sarcoma · Phase 2 · terminated
- NCT04383119 — Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03773510 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Italian Sarcoma Group
- Last refreshed: 13 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03773510.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing